陈东

学术任务

日期	时间	会场	任务类型	Session	题目
2026-06-14	11:25-11:35	分会场3(C202会议室)	专题发言	肿瘤分会场：Session IV	Characterization of Patients Responding to Enfortumab Vedotin Plus Pembrolizumab (EV+P): Exploratory Analysis From the Phase 3 EV-302 Trial of EV+P versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)